ClinicalTrials.gg
CompletedNCT00141063Updated Dec 21, 2007

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

A Phase 3 interventional study of Focalin XR in ADHD, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2007-12-21.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis — none open to participants now, none under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Novartis.

Enrollment
8th of 10
90 · median 146
Started
2005
with 2 others
Phase 3
7 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, this one is the 8th largest by enrollment, is one of 3 that started in 2005, is one of 7 in phase 3, and was the 1st registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

None of the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis is open now. The open studies under Attention Deficit Disorder with Hyperactivity, anywhere →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.

03

Conditions studied

  • ADHD

Keywords

  • ADHD, children
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of ADHD
  • Males and females aged 6-12

Exclusion criteria

Exclusion Criteria:

  • Inability of understand or follow instructions
  • Is pregnant
  • Diagnosis of tic disorder
  • History of seizure disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
90 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in attention and deportment measured at 2 hours post-dose

Secondary outcomes

  1. Onset of effect at 0.5, 1, 2, 3, 4, 6, 8, 10, 11, and 12 hours post-dose

  2. Parent's assessment of patient behavior across all treatment periods as measured by the change from baseline

  3. Safety and tolerability of two doses of dexmethylphenidate compared to two doses of an approved, long-acting, marketed medication for ADHD and placebo in children ages 6-12 diagnosed with ADHD.

07

Study locations

1 site
  • Center for Psychiatry & Behavioral Medicine
    Las Vegas, Nevada 89128, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Jun 2005
CompletionActual
Aug 2005
Last update
Dec 21, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00141063
Lead sponsor
Novartis
First posted
Sep 1, 2005
Start date
Jun 2005
Completion
Aug 2005
Last update
Dec 21, 2007

Study contacts

Ann Childress, MD
principal investigator · Center for Psychiatry and Behavioral Medicine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmethylphenidate

Start the discussion